Oculis Holding AG (Oculis Holding AG) Debt-to-Asset : 0.01 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Debt-to-Asset?

Oculis Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.21 Mil. Oculis Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.46 Mil. Oculis Holding AG's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $111.09 Mil. Oculis Holding AG's debt to asset for the quarter that ended in Mar. 2024 was 0.01.

Oculis Holding AG Debt-to-Asset Historical Data

The historical data trend for Oculis Holding AG's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Debt-to-Asset Chart

Oculis Holding AG Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.05

0.01

0.02

0.01

Oculis Holding AG Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial							-	0.01	0.01	0.01	0.01

Competitive Comparison of Oculis Holding AG's Debt-to-Asset

For the Biotechnology subindustry, Oculis Holding AG's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oculis Holding AG's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's Debt-to-Asset falls into.

Oculis Holding AG Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Oculis Holding AG's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.201	+	0.498)	/	132.231
	=	0.01

Oculis Holding AG's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.205	+	0.463)	/	111.088
	=	0.01

Oculis Holding AG (NAS:OCS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Oculis Holding AG Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Oculis Holding AG (Oculis Holding AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

CR5:Germany

Address

Bahnhofstrasse 7, Zug, CHE, 6300

Website

https://www.oculis.com

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.